Latest News

Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 24th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as... Read More

VIRALEZE UK update (ASX Announcement)

Jun 21st, 2021

Melbourne, Australia; 21 June 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) advises that its UK retail partner, LloydsPharmacy, has received correspondence from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in relation to specific promotional claims made for VIRALEZE™ antiviral nasal spray. The correspondence relates to promotional claims, including references to... Read More

VIRALEZE SPL7013 virucidal against multiple COVID variants (ASX Announcement)

Jun 18th, 2021

Further antiviral testing has confirmed SPL7013 (VIRALEZE active) has potent virucidal activity against the Alpha (UK), Beta (South Africa) and Gamma (Japan/Brazil) variant strains of SARS-CoV-2 coronavirus

Read More

VIRALEZE antiviral nasal spray registered for sale in India (ASX Announcement)

Jun 11th, 2021

... VIRALEZE™ has been registered for sale nationally in India ... VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013) which is virucidal, irreversibly inactivating >99.9% of SARS-CoV-2 (the virus that causes COVID-19) within one minute[1] ... The active in VIRALEZE™ is also highly active against multiple strains and... Read More

In the media

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.

Read More

Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18th, 2021

News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

"New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus," as reported by the New Delhi Times. Read the full article here.

Read More

Shareholder Updates

VIRALEZE SPL7013 highly active in UK variant of coronavirus (ASX Announcement)

Jun 1st, 2021

New antiviral testing at the Scripps Research Institute has confirmed SPL7013 (VIRALEZE active) has potent antiviral activity against the UK (B.1.1.7) SARS-CoV-2 coronavirus mutant/variant strain.

Read More

Shareholder Newsletter

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Read More

Sign up to receive news here